Literature DB >> 20619389

Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCA1/2 mutation carriers?

Mark H Greene1, Phuong L Mai, Peter E Schwartz.   

Abstract

Risk-reducing salpingo-oophorectomy (RRSO) is the most definitive surgical intervention for ovarian cancer risk reduction among BRCA1/2 mutation carriers. For women who have completed child-bearing but who are not ready for RRSO, bilateral salpingectomy with ovarian retention (BSOR) might serve as a temporary measure while definitive risk-reducing surgery is being contemplated. Here we summarize recent insights into the pathogenesis of hereditary ovarian cancer that might provide a basis for consideration of the proposed BSOR management strategy and outline the evidence for and against this potential risk-reducing intervention. Based on the evidence, we suggest that there may be sufficient merit in this proposed intervention to consider evaluating it formally, perhaps through an intergroup-based clinical trial. In the meanwhile, we believe that BSOR should be considered an investigational risk management option of unproven clinical usefulness, particularly because delay in bilateral oophorectomy theoretically could reduce the protective effect against breast cancer that has been documented in women who have undergone RRSO. Published by Mosby, Inc.

Entities:  

Mesh:

Year:  2010        PMID: 20619389      PMCID: PMC3138129          DOI: 10.1016/j.ajog.2010.05.038

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  44 in total

1.  Pathologic findings in prophylactic oophorectomy specimens in high-risk women.

Authors:  Katherine Leeper; Rochelle Garcia; Elizabeth Swisher; Barbara Goff; Benjamin Greer; Pamela Paley
Journal:  Gynecol Oncol       Date:  2002-10       Impact factor: 5.482

2.  Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status.

Authors:  T J Colgan; J Murphy; D E Cole; S Narod; B Rosen
Journal:  Am J Surg Pathol       Date:  2001-10       Impact factor: 6.394

3.  Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer.

Authors:  J M Piek; P J van Diest; R P Zweemer; J W Jansen; R J Poort-Keesom; F H Menko; J J Gille; A P Jongsma; G Pals; P Kenemans; R H Verheijen
Journal:  J Pathol       Date:  2001-11       Impact factor: 7.996

4.  Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.

Authors:  S A Narod; P Sun; P Ghadirian; H Lynch; C Isaacs; J Garber; B Weber; B Karlan; D Fishman; B Rosen; N Tung; S L Neuhausen
Journal:  Lancet       Date:  2001-05-12       Impact factor: 79.321

5.  Unexpected gynecologic neoplasms in patients with proven or suspected BRCA-1 or -2 mutations: implications for gross examination, cytology, and clinical follow-up.

Authors:  S Nicholas Agoff; Joel E Mendelin; Verena S Grieco; Rochelle L Garcia
Journal:  Am J Surg Pathol       Date:  2002-02       Impact factor: 6.394

6.  Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy.

Authors:  K H Lu; J E Garber; D W Cramer; W R Welch; J Niloff; D Schrag; R S Berkowitz; M G Muto
Journal:  J Clin Oncol       Date:  2000-07       Impact factor: 44.544

7.  Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.

Authors:  H A Risch; J R McLaughlin; D E Cole; B Rosen; L Bradley; E Kwan; E Jack; D J Vesprini; G Kuperstein; J L Abrahamson; I Fan; B Wong; S A Narod
Journal:  Am J Hum Genet       Date:  2001-02-15       Impact factor: 11.025

Review 8.  Precursors to pelvic serous carcinoma and their clinical implications.

Authors:  Ann K Folkins; Elke A Jarboe; Michael H Roh; Christopher P Crum
Journal:  Gynecol Oncol       Date:  2009-02-23       Impact factor: 5.482

9.  Expression of differentiation and proliferation related proteins in epithelium of prophylactically removed ovaries from women with a hereditary female adnexal cancer predisposition.

Authors:  J M J Piek; R H M Verheijen; F H Menko; A P M Jongsma; J Weegenaar; J J P Gille; G Pals; P Kenemans; P J van Diest
Journal:  Histopathology       Date:  2003-07       Impact factor: 5.087

10.  Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up.

Authors:  R I Olivier; M van Beurden; M A C Lubsen; M A Rookus; T M Mooij; M J van de Vijver; L J van't Veer
Journal:  Br J Cancer       Date:  2004-04-19       Impact factor: 7.640

View more
  27 in total

1.  Targeting progesterone signaling prevents metastatic ovarian cancer.

Authors:  Olga Kim; Eun Young Park; Sun Young Kwon; Sojin Shin; Robert E Emerson; Yong-Hyun Shin; Francesco J DeMayo; John P Lydon; Donna M Coffey; Shannon M Hawkins; Lawrence A Quilliam; Dong-Joo Cheon; Facundo M Fernández; Kenneth P Nephew; Adam R Karpf; Martin Widschwendter; Anil K Sood; Robert C Bast; Andrew K Godwin; Kathy D Miller; Chi-Heum Cho; Jaeyeon Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2020-12-01       Impact factor: 11.205

2.  Examining the use of salpingectomy with hysterectomy in Canada.

Authors:  C Sandoval; M Fung-Kee-Fung; B Gilks; K J Murphy; R Rahal; H Bryant
Journal:  Curr Oncol       Date:  2013-06       Impact factor: 3.677

3.  Fallopian tube removal: "stic-ing" it to ovarian cancer: what is the utility of prophylactic tubal removal?

Authors:  T J Herzog; H E Dinkelspiel
Journal:  Curr Oncol       Date:  2013-06       Impact factor: 3.677

Review 4.  Ovarian Cancer Prevention in High-risk Women.

Authors:  Sarah M Temkin; Jennifer Bergstrom; Goli Samimi; Lori Minasian
Journal:  Clin Obstet Gynecol       Date:  2017-12       Impact factor: 2.190

5.  Opportunistic Salpingectomy as an Ovarian Cancer Primary Prevention Strategy.

Authors:  Geetha Balsarkar
Journal:  J Obstet Gynaecol India       Date:  2017-05-11

Review 6.  Risk-Reducing Strategies for Ovarian Cancer in BRCA Mutation Carriers: A Balancing Act.

Authors:  Roi Tschernichovsky; Annekathryn Goodman
Journal:  Oncologist       Date:  2017-03-17

7.  Primary culture and immortalization of human fallopian tube secretory epithelial cells.

Authors:  Alison M Karst; Ronny Drapkin
Journal:  Nat Protoc       Date:  2012-08-30       Impact factor: 13.491

8.  Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy.

Authors:  C B Powell; E M Swisher; I Cass; J McLennan; B Norquist; R L Garcia; J Lester; B Y Karlan; L Chen
Journal:  Gynecol Oncol       Date:  2013-02-04       Impact factor: 5.482

Review 9.  Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence.

Authors:  Mark E Sherman; Ronny I Drapkin; Neil S Horowitz; Christopher P Crum; Sue Friedman; Janice S Kwon; Douglas A Levine; Ie-Ming Shih; Donna Shoupe; Elizabeth M Swisher; Joan Walker; Britton Trabert; Mark H Greene; Goli Samimi; Sarah M Temkin; Lori M Minasian
Journal:  Cancer Prev Res (Phila)       Date:  2016-05-24

10.  Fallopian Tube Ligation or Salpingectomy as Means for Reducing Risk of Ovarian Cancer.

Authors:  J Brian Szender; Shashikant B Lele
Journal:  AMA J Ethics       Date:  2015-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.